These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 19629166)

  • 1. Positive epistasis drives the acquisition of multidrug resistance.
    Trindade S; Sousa A; Xavier KB; Dionisio F; Ferreira MG; Gordo I
    PLoS Genet; 2009 Jul; 5(7):e1000578. PubMed ID: 19629166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant bacteria compensate for the epistasis between resistances.
    Moura de Sousa J; Balbontín R; Durão P; Gordo I
    PLoS Biol; 2017 Apr; 15(4):e2001741. PubMed ID: 28419091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Resistance at No Cost: Rifampicin and Streptomycin a Dangerous Liaison in the Spread of Antibiotic Resistance.
    Durão P; Trindade S; Sousa A; Gordo I
    Mol Biol Evol; 2015 Oct; 32(10):2675-80. PubMed ID: 26130082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolutionary Mechanisms Shaping the Maintenance of Antibiotic Resistance.
    Durão P; Balbontín R; Gordo I
    Trends Microbiol; 2018 Aug; 26(8):677-691. PubMed ID: 29439838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pervasive sign epistasis between conjugative plasmids and drug-resistance chromosomal mutations.
    Silva RF; Mendonça SC; Carvalho LM; Reis AM; Gordo I; Trindade S; Dionisio F
    PLoS Genet; 2011 Jul; 7(7):e1002181. PubMed ID: 21829372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictable Phenotypes of Antibiotic Resistance Mutations.
    Knopp M; Andersson DI
    mBio; 2018 May; 9(3):. PubMed ID: 29764951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pervasive Pairwise Intragenic Epistasis among Sequential Mutations in TEM-1 β-Lactamase.
    Gonzalez CE; Ostermeier M
    J Mol Biol; 2019 May; 431(10):1981-1992. PubMed ID: 30922874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Epistasis between beneficial mutations in an antibiotic resistance gene.
    Schenk MF; Szendro IG; Salverda ML; Krug J; de Visser JA
    Mol Biol Evol; 2013 Aug; 30(8):1779-87. PubMed ID: 23676768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceleration and suppression of resistance development by antibiotic combinations.
    Suzuki S; Horinouchi T; Furusawa C
    BMC Genomics; 2017 Apr; 18(1):328. PubMed ID: 28446153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epistatic interactions determine the mutational pathways and coexistence of lineages in clonal Escherichia coli populations.
    Maharjan RP; Ferenci T
    Evolution; 2013 Sep; 67(9):2762-8. PubMed ID: 24033182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epistasis analysis uncovers hidden antibiotic resistance-associated fitness costs hampering the evolution of MRSA.
    Yokoyama M; Stevens E; Laabei M; Bacon L; Heesom K; Bayliss S; Ooi N; O'Neill AJ; Murray E; Williams P; Lubben A; Reeksting S; Meric G; Pascoe B; Sheppard SK; Recker M; Hurst LD; Massey RC
    Genome Biol; 2018 Jul; 19(1):94. PubMed ID: 30021593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epistasis between antibiotic tolerance, persistence, and resistance mutations.
    Levin-Reisman I; Brauner A; Ronin I; Balaban NQ
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14734-14739. PubMed ID: 31262806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for adaptation overrides cost of resistance.
    Moura de Sousa J; Sousa A; Bourgard C; Gordo I
    Future Microbiol; 2015; 10(9):1415-31. PubMed ID: 26343510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative epistasis between beneficial mutations in an evolving bacterial population.
    Khan AI; Dinh DM; Schneider D; Lenski RE; Cooper TF
    Science; 2011 Jun; 332(6034):1193-6. PubMed ID: 21636772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global epistasis emerges from a generic model of a complex trait.
    Reddy G; Desai MM
    Elife; 2021 Mar; 10():. PubMed ID: 33779543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the Determinants of Evolutionary Dynamics Leading to Drug Resistance.
    Chevereau G; Dravecká M; Batur T; Guvenek A; Ayhan DH; Toprak E; Bollenbach T
    PLoS Biol; 2015; 13(11):e1002299. PubMed ID: 26581035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in Pseudomonas aeruginosa.
    MacLean RC; Perron GG; Gardner A
    Genetics; 2010 Dec; 186(4):1345-54. PubMed ID: 20876562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Survival of Rifampin- and Streptomycin-Resistant Escherichia coli Inside Macrophages.
    Durão P; Gülereşi D; Proença J; Gordo I
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4324-32. PubMed ID: 27161646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epistasis between new mutations and genetic background and a test of genetic canalization.
    Elena SF; Lenski RE
    Evolution; 2001 Sep; 55(9):1746-52. PubMed ID: 11681730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant resistance and negative epistasis can limit the co-selection of de novo resistance mutations and antibiotic resistance genes.
    Porse A; Jahn LJ; Ellabaan MMH; Sommer MOA
    Nat Commun; 2020 Mar; 11(1):1199. PubMed ID: 32139686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.